DCAT Value Chain Insights

Blockbuster Watch: Small Molecules and Biologics

Which of the new drugs expected to launch in 2021 have blockbuster potential (defined as products with sales of $1 billion or more)? What are revenue projections, and what is the mix between small...

President Biden Calls for Review of US Drug Supply Chain

Supply-chain vulnerabilities exposed during the COVID-19 pandemic as well as those existing pre-pandemic were behind an executive order signed by President Joe Biden late last month (February 2021)...

SPONSORED CONTENT

Supply Chain Security -- If Your API Supply Is Important, You Should Take Five Minutes To Read This

Information
February 24, 2021
Sponsored by ChemWerth

We all know that active pharmaceutical ingredient (API) end user supply chain security is a critical component to getting the finished dosage to market. Securing the supply chain means that...

Read More
Embarking Upon the Commercial Manufacturing Journey for a Biologic: Strategies to Achieve Successful Approval & Launch

Information
February 10, 2021
Sponsored by Catalent Biologics

In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon...

Read More
Build or Buy Challenge: Six Advantages of Using a Pre-Qualified, Fully Customizable GMP Environment

Information
January 27, 2021
Sponsored by Almac

Today, biopharma companies face growing challenges when capacity is at a premium. Investment decisions must be made to ultimately determine the expansion of facilities, headcounts and technology...

Read More